Company intelligence / Profile preview

Caerus Biotech

Ownership: Private
Employees: ~4
Development stage: Commercial

Overview

Caerus Biotech has developed and commercialized MiOXSYS®, an internationally protected, clinically proven, and WHO-recognized diagnostic platform for assessing male infertility. The technology provides accurate results to help plan fertility treatments and improve patient outcomes by addressing previously understudied factors in male reproductive health.

Therapeutic areas: Men's Health
Modalities: Device (in-vitro diagnostic tool)
Industry: Metabolite Diagnostics

Partnerships

MicroMed Solutions – manufacturing partner for device compliance and production of MiOXSYS®

Beyond the preview

Go deeper on Caerus Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caerus Biotech.

Explore the full profile